New markers for separating benign from malignant mesothelial proliferations: Are we there yet?

Archives of Pathology and Laboratory Medicine

Volumn 140, Issue 4, 2016, Pages 318-321

  Churg, Andrew ^a   Sheffield, Brandon S ^a   Galateau Salle, Francoise ^b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CAEN UNIVERSITY HOSPITAL   (France)

^c CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BAP1 PROTEIN, HUMAN; MUCIN 1; P16 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

CELL PROLIFERATION; DIFFERENTIAL DIAGNOSIS; EPITHELIUM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MESOTHELIOMA; METABOLISM; PATHOLOGY; PERITONEUM TUMOR; PLEURA; PLEURA TUMOR;

BIOMARKERS, TUMOR; CELL PROLIFERATION; DIAGNOSIS, DIFFERENTIAL; EPITHELIUM; FEMALE; GENE DELETION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MESOTHELIOMA; MUCIN-1; NEOPLASM PROTEINS; PERITONEAL NEOPLASMS; PLEURA; PLEURAL NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84964068247     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2015-0240-SA     Document Type: Article

References (43)

1. Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000;24(9):1183-1200.
2. Churg A, Galateau-Salle F. The separation of benign and malignant mesothelial proliferations. Arch Pathol Lab Med. 2012;136(10):1217-1226.
3. Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S. Challenges and controversies in the diagnosis of mesothelioma: part 1, cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol. 2013;66(10): 847-853.
4. Galateau-Salle F, Churg A, Roggli VL, et al. Epithelioid mesothelioma. In, Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart. 4th ed. Lyon, France: IARC Press; 2015:156-164. World Health Organization Classification of Tumours; vol 7.
5. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20(2):215-220.
6. Chang S, Oh MH, Ji SY, et al. Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations. Pathol Int. 2014;64(12):607-612.
7. Minato H, Kurose N, Fukushima M, et al. Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells. Am J Clin Pathol. 2014; 141(1):85-93.
8. Lee AF, Gown AM, Churg A. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations. Am J Surg Pathol. 2013;37(3):421-426.
9. Monaco SE, Shuai Y, Bansal M, Krasinskas AM, Dacic S. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol. 2011;135(4):619-627.
10. Shen J, Pinkus GS, Deshpande V, Cibas ES. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol. 2009;131(4):516-523.
11. Lagana SM, Taub RN, Borczuk AC. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions. Arch Pathol Lab Med. 2012;136(7):804-809.
12. McCluggage WG, Soslow RA, Gilks CB. Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance. Histopathology. 2011;59(4):786-788.
13. Kaye PV, Haider SA, James PD, et al. Novel staining pattern of p53 in Barrett's dysplasia-the absent pattern. Histopathology. 2010;57(6):933-935.
14. Hellberg D, Tot T, Stendahl U. Pitfalls in immunohistochemical validation of tumor marker expression-exemplified in invasive cancer of the uterine cervix. Gynecol Oncol. 2009;112(1):235-240.
15. Guo G, Chmielecki J, Goparaju C, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015;75(2):264-269.
16. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003;43(3): 231-238.
17. Shi M, Fraire AE, Chu P, et al. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol. 2011;35(6):878-882.
18. King J, Thatcher N, Pickering C, Hasleton P. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology. 2006;49(6):561-568.
19. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237-6242.
20. Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis. 2002;23(7):1127-1130.
21. Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. Int J Cancer. 2012;130(8):1715-1725.
22. Tochigi N, Attanoos R, Chirieac LR, Allen TC, Cagle PT, Dacic S. p16 deletion in sarcomatoid tumors of the lung and pleura. Arch Pathol Lab Med. 2013;137(5):632-636.
23. Liggett WH Jr, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol. 1998;16(3):1197-1206.
24. Ladanyi M. Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer. 2005;49(suppl 1):S95-S98.
25. Krasinskas AM, Bartlett DL, Cieply K, Dacic S. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod Pathol. 2010;23(4):531-538.
26. Illei PB, Ladanyi M, Rusch VW, Zakowski MF. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer. 2003;99(1):51-56.
27. Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol. 2008;21(6):742-747.
28. Dacic S, Kothmaier H, Land S, et al. Prognostic significance of p16/ cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch. 2008;453(6): 627-635.
29. Chung CT, SantosGda C, Hwang DM, et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol. 2010;63(7):630-634.
30. Ladanyi M, Zauderer MG, Krug LM, et al. New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res. 2012;18(17):4485-4490.
31. Nasu M, Emi M, Pastorino S, et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015;10(4): 565-576.
32. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668-672.
33. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022-1025.
34. Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology. 2013;45(2):116-126.
35. Njauw CN, Kim I, Piris A, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One. 2012;7(4):e35295.
36. Farzin M, Toon CW, Clarkson A, et al. Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology. 2015;47(4):302-307.
37. Yoshikawa Y, Sato A, Tsujimura T, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci. 2012;103(5):868-874.
38. Cigognetti M, Lonardi S, Fisogni S, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 28(8):1043-1057.
39. Sheffield BS, Hwang HC, Lee AF, et al. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol. 2015;39(7):77-82.
40. Takeda M, Kasai T, Enomoto Y, et al. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int. 2010;60(5):395-399.
41. Wu D, Hiroshima K, Matsumoto S, et al. Diagnostic usefulness of p16/ CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. Am J Clin Pathol. 2013;139(1):39-46.
42. Hwang H, Tse C, Rodriguez S, Gown A, Churg A. p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma. Am J Surg Pathol. 2014;38(5):681-688.
43. Ito T, Hamasaki M, Matsumoto S, et al. p16/CDKN2A FISH in differentiation of diffuse malignant peritoneal mesothelioma from mesothelial hyperplasia and epithelial ovarian cancer. Am J Clin Pathol. 2015;143(6):830-838.